首页> 外文期刊>Japanese Journal of Cancer Research >Estrone and 17beta-Estradiol Reverse Breast Cancer Resistance Protein-mediated Multidrug Resistance.
【24h】

Estrone and 17beta-Estradiol Reverse Breast Cancer Resistance Protein-mediated Multidrug Resistance.

机译:雌酮和17β-雌二醇逆转乳腺癌耐药性蛋白介导的多药耐药性。

获取原文
获取原文并翻译 | 示例
           

摘要

Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan. In the present study, we found that estrone and 17beta-estradiol potentiated the cytotoxicity of mitoxantrone, SN-38 and topotecan in BCRP-transduced K562 cells (K562 / BCRP). These estrogens showed only a marginal effect, or none, in parental K562 cells. Estrone and 17beta-estradiol increased the cellular accumulation of topotecan in K562 / BCRP cells, but not in K562 cells, suggesting that these estrogens inhibit the BCRP-mediated drug efflux and overcome drug resistance.
机译:乳腺癌抗性蛋白(BCRP)是一种结合三磷酸腺苷的盒式转运蛋白,可赋予对一系列抗癌剂(包括米托蒽醌,SN-38和托泊替康)的抗性。在本研究中,我们发现雌酮和17β-雌二醇可增强米托蒽醌,SN-38和托泊替康对BCRP转导的K562细胞(K562 / BCRP)的细胞毒性。这些雌激素在亲代K562细胞中仅显示出边缘作用,或没有。雌酮和17β-雌二醇可增加拓扑替康在K562 / BCRP细胞中的细胞蓄积,但不会在K562细胞中增加,表明这些雌激素抑制BCRP介导的药物外流并克服了耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号